CA Patent

CA2381111A1 — Npy antagonists: spiroisoquinolinone derivatives

Assigned to Bristol Myers Squibb Co · Expires 2001-03-01 · 25y expired

What this patent protects

A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of spiroisoquinolinone derivatives of Formula (I). As antagonists of NPY-induced feeding behavior, these compounds and known analogs are expected to act as effective anorexiant agents in prom…

USPTO Abstract

A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of spiroisoquinolinone derivatives of Formula (I). As antagonists of NPY-induced feeding behavior, these compounds and known analogs are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.

Drugs covered by this patent

Patent Metadata

Patent number
CA2381111A1
Jurisdiction
CA
Classification
—
Expires
2001-03-01
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.